Literature DB >> 10404882

Efficient inactivation of viruses and mycoplasma in animal sera using UVC irradiation.

J Kurth1, R Waldmann, J Heith, K Mausbach, R Burian.   

Abstract

Transmission of viruses by animal sera represents a considerable risk for humans and animals particularly when the serum is used for the production of pharmaceutical products such as vaccines. Procedures applicable for inactivating large numbers of different viruses, both enveloped and non-enveloped, are therefore mandatory. For this purpose we have developed and validated UVC irradiation as the virus-inactivation procedure of choice for serum to be used in an industrial setting. Spiking experiments in foetal calf serum (FCS) were performed by independent contract laboratories and revealed constantly high clearance rates for various viruses such as bovine parvovirus, parainfluenza type III virus, bovine diarrhoea virus, foot-and-mouth disease virus and different forms of mycoplasmas. UVC-treated sera maintained their growth-promoting activities for various cell types (MRC-5, Vero, CHO). Conventional growth curves generated in the presence of 10% and 1% UVC-treated FCS differed only slightly from controls, indicating the lack of significant damage during UVC exposure. Experiments using a sensitive photometric-based acid phosphatase assay (APA), which correlates well with the more tedious cell counting procedure, confirmed these findings even in the presence of minimal serum requirements. UVC treatment of animal sera appears advantageous compared to currently recommended inactivation procedures, such as Gamma irradiation, for at least three reasons: (i) it possesses a high inactivation capacity for parvoviruses, a pathogen that cannot be destroyed easily by conventional methods; (ii) it causes no noticeable impairment in cell growth and (iii) it can be performed in a controlled manner at the production site.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404882

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  5 in total

1.  Effect of storage conditions on detection of mycoplasma in biopharmaceutical products.

Authors:  Hsiu-Shuei Cheng; Chiu-Wen Shen; Shih-Rong Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-03-31       Impact factor: 2.416

2.  Serum-free produced Bovine Herpesvirus type 1 and Bovine Parainfluenza type 3 virus vaccines are efficacious and safe.

Authors:  B Makoschey; J R Patel; P T J A van Gelder
Journal:  Cytotechnology       Date:  2002-09       Impact factor: 2.058

Review 3.  Evaluating ultraviolet sensitivity of adventitious agents in biopharmaceutical manufacturing.

Authors:  Sarah M Meunier; Michael R Sasges; Marc G Aucoin
Journal:  J Ind Microbiol Biotechnol       Date:  2017-03-10       Impact factor: 3.346

4.  Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies.

Authors:  Devon J Eddins; Leda C Bassit; Joshua D Chandler; Natalie S Haddad; Kathryn L Musall; Junkai Yang; Astrid Kosters; Brian S Dobosh; Mindy R Hernández; Richard P Ramonell; Rabindra M Tirouvanziam; F Eun-Hyung Lee; Keivan Zandi; Raymond F Schinazi; Eliver E B Ghosn
Journal:  Immunohorizons       Date:  2022-02-16

5.  Virus contaminations of cell cultures - A biotechnological view.

Authors:  O-W Merten
Journal:  Cytotechnology       Date:  2002-07       Impact factor: 2.058

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.